Chronic kidney disease (CKD), like many complex disease traits, manifests from dependent interactions between genetic susceptibilities and environmental factors. The recently described APOL1 risk alleles associated with CKD and African Ancestry is one example, where only a portion of genetically-susceptible patients develop kidney disease, suggesting a second hit or stress is required to trigger variant APOL1- dependent kidney injury. To investigate the mechanism of APOL1 variants in CKD, we have chosen to focus on HIV-associated nephropathy (HIVAN), the disease most robustly associated with APOL1 risk haplotypes and clearly dependent on an environmental factor, HIV-1 infection. Our preliminary data demonstrate APOL1 is expressed in the podocyte, and APOL1 overexpression activates autophagy. Although mTor-induced core autophagy pathways have been implicated in the glomerular injury of diabetic nephropathy -- a renal pathology not associated with APOL1 variants -- we have evidence that selective autophagy pathways involving destruction of pathogens may be uniquely regulated by APOL1. We hypothesize that APOL1 functions as an autophagocytic adaptor by binding to both a docking SNARE (VAMP8) displayed on endosomes and to the autophagosomal protein LC3-II. The autophagocytic adaptor function of APOL1 is activated by binding a triggering molecule, such as the HIV protein Nef after infection, and results in the selective degradation of VAMP8-labeled endosomal cargo including viral particles and proteins. Variant APOL1 proteins are functionally defective, permitting HIV to persist in the infected cell, and supporting the new synthesis of Nef, the HIV protein critical for development of HIVAN. Our proposed experiments will address three unanswered and novel questions regarding APOL1 function in CKD. Is APOL1 synthesized in situ in kidney and what is its subcellular home? Does circulating or renal-expressed variant APOL1 mediate kidney disease? Does dysregulation of autophagy pathways activated in response to specific environmental stresses result in kidney disease in patients with APOL1 risk genotypes? These questions will be addressed with the following Specific Aims: 1. Determine APOL1 expression and intracellular location in normal kidney, and determine if APOL1 localization varies with risk genotype and/or disease diagnosis; 2. Generate in vivo models for the study of APOL1 function; 3. Characterize protein interactions between APOL1 with VAMP8 and the HIV protein Nef. Examine the effect of normal and variant APOL1 expression on autophagy in cell lines and cultured podocytes. Focusing on the unique pathways though which APOL1 regulates autophagy will most likely result in novel, mechanism-based therapies. Determining how APOL1 variation is associated with human kidney diseases will provide a unique opportunity to understand pathways causing common chronic kidney disease and use of that knowledge can be exploited to develop new strategies for therapy, prevention and risk stratification.

Public Health Relevance

Approximately 26 million Americans have evidence for chronic kidney disease (CKD) and more than 570,000 patients have kidney failure (end-stage renal disease [ESRD]). Health care for CKD and ESRD patients accounts for 33% of Medicare expenditures. These patients are at risk for associated complications, including accelerated cardiovascular disease and early death. African American and other minority CKD patients in the United States are four times more likely than white patients to progress to ESRD, and a single genetic susceptibility locus (APOL1) explains much of this increased risk. This project's goal is to define biological reasons for the association of APOL1 with CKD in patients with African ancestry in order to improve outcomes in this high-risk population.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
High Priority, Short Term Project Award (R56)
Project #
1R56DK097836-01
Application #
8548032
Study Section
Pathobiology of Kidney Disease Study Section (PBKD)
Program Officer
Kimmel, Paul
Project Start
2012-09-30
Project End
2014-09-29
Budget Start
2012-09-30
Budget End
2014-09-29
Support Year
1
Fiscal Year
2012
Total Cost
$198,000
Indirect Cost
$71,885
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Madhavan, Sethu M; O'Toole, John F; Konieczkowski, Martha et al. (2017) APOL1 variants change C-terminal conformational dynamics and binding to SNARE protein VAMP8. JCI Insight 2:
O'Toole, John F; Bruggeman, Leslie A; Madhavan, Sethu et al. (2017) The Cell Biology of APOL1. Semin Nephrol 37:538-545
Bruggeman, Leslie A; O'Toole, John F; Sedor, John R (2017) Identifying the Intracellular Function of APOL1. J Am Soc Nephrol 28:1008-1011
O'Toole, John F; Bruggeman, Leslie A; Sedor, John R (2017) APOL1 and Proteinuria in the AASK: Unraveling the Pathobiology of APOL1. Clin J Am Soc Nephrol 12:1723-1725
Bruggeman, Leslie A; Wu, Zhenzhen; Luo, Liping et al. (2016) APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease. J Am Soc Nephrol 27:3600-3610
Madhavan, Sethu M; O'Toole, John F (2014) The biology of APOL1 with insights into the association between APOL1 variants and chronic kidney disease. Clin Exp Nephrol 18:238-42
O'Toole, John F; Sedor, John R (2014) Kidney disease: new technologies translate mechanisms to cure. J Clin Invest 124:2294-8
Böger, Carsten A; Sedor, John R (2012) GWAS of diabetic nephropathy: is the GENIE out of the bottle? PLoS Genet 8:e1002989